Sanofi: EPS up over a quarter in 2022

(CercleFinance.com) - Sanofi reports business EPS of E8.
26 for 2022, up 25.9% (+17.1% at constant exchange rates), and says that it has achieved its medium-term targets of a 30% operating margin and E
2.5 billion euros in cost savings.

The healthcare group's sales rose by 13.9% (+7% at CER) to 43 billion euros, supported by Dupixent (+43.8%), the performance of vaccines (+6.3%) in line with its medium-term targets and the execution of the consumer healthcare strategy (+8.6%).

At its meeting on 2 February, the Board of Directors proposed a dividend of 3.56 euros per share, up 6.9%. Sanofi expect low single-digit 2023 business EPS growth at CER, barring major unforeseen adverse events.


Copyright (c) 2023 CercleFinance.com. All rights reserved.